Protein Therapeutics Market Witnesses Robust Growth Rate of 7.1%, Exceeding USD 566.66 Bn by 2030

What is the market for protein therapeutics?

As per the report, the global protein therapeutics industry accounted for $283.64 billion in 2020, and is expected to reach $566.66 billion by 2030, growing at a CAGR of 7.1% from 2021 to 2030.

Key Takeaways:

Significant Growth: The protein therapeutics market has experienced significant growth over the years. This is driven by factors such as increasing prevalence of chronic diseases (such as cancer, diabetes, and autoimmune disorders), advancements in biotechnology, and a better understanding of the molecular mechanisms of diseases.

Diverse Range of Products: Protein therapeutics encompass a diverse range of products, including monoclonal antibodies, growth factors, enzymes, hormones, cytokines, and fusion proteins. These products are designed to target specific disease mechanisms and pathways.

Monoclonal Antibodies (mAbs) Dominate: Monoclonal antibodies have been a dominant class of protein therapeutics. They are widely used for cancer treatment, autoimmune diseases, and other conditions due to their high specificity and relatively low side effects compared to traditional treatments.

Biotechnology Advancements: Advances in biotechnology, including genetic engineering and recombinant DNA technology, have revolutionized the production of protein therapeutics. These techniques allow for the efficient and consistent production of complex proteins in large quantities.

Personalized Medicine: Protein therapeutics have contributed to the rise of personalized medicine. By targeting specific molecular pathways associated with individual patients’ diseases, these therapies can offer more tailored and effective treatments.

Request Sample Copy of Report: 

https://www.alliedmarketresearch.com/request-sample/60

Covid-19 scenario:

• The Covid-19 pandemic had a positive impact on the growth of protein therapeutics due to surge in chronic diseases and increase in demand for therapeutic drugs.
• The number of clinics and hospitals across the globe increased during the pandemic, which supplemented the demand for protein therapeutics.
• However, the prolonged lockdown and disruptions of manufacturing and transportation of healthcare essentials hinder the market.

Market Drivers:

Increasing Prevalence of Chronic Diseases: The rising incidence of chronic diseases, such as cancer, diabetes, autoimmune disorders, and cardiovascular diseases, has created a significant demand for effective treatments. Protein therapeutics offer targeted approaches to managing these conditions, which has driven their development and adoption.

Advancements in Biotechnology: Breakthroughs in biotechnology, including genetic engineering, recombinant DNA technology, and protein expression systems, have made it possible to produce complex proteins on a larger scale and with greater precision. This has enabled the development of a wide range of protein therapeutics.

Personalized Medicine: The shift towards personalized medicine has led to the development of targeted therapies tailored to individual patients’ genetic and molecular profiles. Protein therapeutics can be designed to interact with specific molecular pathways and targets, allowing for more precise and effective treatments.

Request for Customization – 

https://www.alliedmarketresearch.com/request-for-customization/60

Market Segmentation:

Product Type:

• • Monoclonal Antibodies (mAbs): These are a major category of protein therapeutics and can be further classified based on their target and application.
  • Enzymes: Proteins that catalyze biochemical reactions in the body.
  • Hormones: Regulatory proteins that control various physiological processes.
  • Cytokines: Signaling proteins involved in immune responses and cell communication.
  • Fusion Proteins: Engineered proteins that combine the functions of two or more proteins.
  • Peptide Therapeutics: Short chains of amino acids with therapeutic properties.
  • Others: Including growth factors, blood factors, and clotting factors.

Therapeutic Area:

• • Oncology: Protein therapeutics used to treat various types of cancer.
  • Autoimmune Diseases: Conditions where the immune system attacks the body’s own tissues.
  • Infectious Diseases: Protein-based therapies targeting viral or bacterial infections.
  • Metabolic Disorders: Disorders related to metabolism and hormone regulation.
  • Neurological Disorders: Protein therapeutics for diseases affecting the nervous system.
  • Cardiovascular Diseases: Protein-based treatments for heart-related conditions.
  • Hematology: Therapies targeting blood-related disorders.
  • Others: Various other therapeutic areas, such as rare diseases.

Technology Platform:

• • Recombinant DNA Technology: Techniques used to produce proteins in host cells.
  • Protein Engineering: Manipulation of protein sequences to enhance properties.
  • Biologics Expression Systems: Different cell lines used for protein expression.
  • Structural Biology: Techniques to study the 3D structures of proteins.
  • Antibody Engineering: Specific techniques for designing and optimizing antibodies.

Geographical Region:

• • North America: Including the United States and Canada.
  • Europe: Including countries within the European Union and other European countries.
  • Asia-Pacific: Including countries like China, Japan, India, and Australia.
  • Latin America: Including countries in Central and South America.
  • Middle East and Africa: Including various countries within these regions.

End User:

• • Hospitals and Clinics: Settings where protein therapeutics are administered to patients.
  • Research Institutions: Organizations conducting research and development in the field.
  • Biotechnology and Pharmaceutical Companies: Companies involved in discovery, development, and commercialization.
  • Others: Government agencies, contract research organizations, and more.

North America held the largest share

By region, the market across North America dominated the market in 2020, holding nearly half of the market, due to increase in chronic diseases, rapid adoption of advanced technologies, and presence of key players in the region. However, the market across Asia-Pacific is expected to register the highest CAGR of 8.7% during the forecast period, owing to rapidly growing geriatric population, surge in public-private investment, and increase in number of initiatives for healthcare awareness.

For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/60

Major market players

• Abbott Laboratories
• Baxter International Inc.
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Merck & Co., Inc.
• Johnson & Johnson (Janssen Pharmaceuticals)
• Pfizer Inc.

Similar Research Reports for Information, Communication and Technology:

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.